Clinical Trials
Clinical trials test new treatments to find better ways to prevent, detect or treat disease. Both healthy people and people with a disease or condition can volunteer to be part of a trial.
Cancer Care Services participate in a range of clinical trials at our hospitals. For information about any of the trials below, ask your doctor or nurse.
For information about clinical trials in general visit the Australian Clinical Trials website or search the Australia and New Zealand Clinical Trials Registry.
| Disease | Trial name | Trial description | Hospital |
|---|---|---|---|
| Acute Leukaemia | ALLG AML M21 | A phase Ib/II clinical evaluation of Ponatinib in combination with 5-azacitidine in FLT3-ITD positive acute myeloid leukaemia AML M21 | RBWH |
| Acute Leukaemia | ALLG NBCR | Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry | RBWH |
| Acute Lymphoblastic Leukaemia | ALLG LS17 REGALLIA | Registry of acute lymphoblastic leukaemia in Australasia associated correlative studies | RBWH |
| Acute Myeloid Leukaemia | MINERAL | Magnetic Resonance Imaging and Quantitative Susceptibility Mapping (MRI-QSM) of brain iron to identify Chemotherapy Associated Neurocognitive Impairment (CANI) in Acute Myeloid Leukaemia (AML) | RBWH |
| Brain | VPA | Evaluation of the role of valproate in the treatment of high grade glioma | RBWH |
| Brain | GBM - BIOMARKERS | Non-Invasive Biomarkers In Glioblastoma - A Pilot Study | RBWH |
| Brain | GBM - HIRF | Using molecular-guided PET/MRI imaging to target hypoxia in glioblastoma: A preclinical study to identify novel pathways and define molecular signatures associated with hypoxia and poor patient outcome | RBWH |
| Brain | ROAM | Radiation versus Observation following surgical resection of Atypical Meningioma: a randomised controlled trial | RBWH |
| Breast | BRCA-P | A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to determine the Preventive Effect of Denosumab on Breast Cancer in Women carrying a BRCA1 Germline Mutation | RBWH |
| Breast | AZTEC | A randomised phase II trial comparing the efficacy of single dose or fractionated SABR (Stereotactic ablative body radiotherapy) with AteZolizumab in patients with advanced Triple nEgative breast Cancer | RBWH |
| Cervical & NSCLC | FMISO PET | Prognostic Value of Assessing Hypoxia in Tumours Using 18FMISO PET During a Course of Radiation Therapy - Proof of Concept Study | RBWH |
| CNS | EX-TEM | Phase III Trial of Extended Temozolomide in Newly Diagnosed Glioblastoma | RBWH |
| CNS | MAGMA | MAGMA Trial: The Multi-Arm GlioblastoMa Australasia Trial | RBWH |
| CNS | NUTMEG | A Randomized Phase II Study of NivolUmab and TeMozolomide vs Temozolomide in newly diagnosed Elderly Glioblastoma | RBWH |
| CNS | KB004 | A phase I safety and bioimaging trial of KB004 in patients with glioblastoma | RBWH |
| EGFR NSCLC | ILLUMINATE | A Phase 2 trial of durvalumab (MEDI4736) and tremelimumab with chemotherapy in metastatic EGFR mutant non-squamous non-small cell lung cancer (NSCLC) following progression on EGFR Tyrosine Kinase Inhibitors (TKIs) | TPCH |
| Genito-Urinary | BEP | A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for participants with intermediate and poor-risk advanced germ cell tumours. | RBWH |
| Genito-Urinary | ePAD | ePAD (Electronic CRPC Australian Database): Analyzing Treatment Patterns and Outcomes from Real-World Patients with Castrate-Resistant Prostate Cancer (CRPC) | RBWH |
| Genito-Urinary | ENZA-p | A randomised phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901) | RBWH |
| Genito-Urinary | MK7339-010 (KEYLYNK 010) | A Phase 3, Randomized, Open-label Study of Pembrolizumab Plus Olaparib Versus Abiraterone Acetate or Enzalutamide in Unselected Participants with mCRPC Who Have Failed Prior Treatment with One Next-generation Hormonal Therapy (NHT) and Chemotherapy. | RBWH |
| Genito-Urinary | UNICAB | A phase II trial of single agent cabozantinib in patients with locally advanced or metastatic non-clear cell renal cell carcinoma post immunotherapy or who are unsuitable for immunotherapy (ANZUP 1802). | RBWH |
| Genito-Urinary | KEYPAD | KidnEY cancer Pembrolizumab And Denosumab: Denosumab and Pembrolizumab in clear cell renal carcinoma: a phase II trial (ANZUP1601) | RBWH |
| Gynaecological | iPRIME | A Phase 2, open label study of durvalumab and tremilimumab in combination with neoadjuvant carboplatin and paclitaxel in newly diagnosed advanced high grade serous ovarian cancer. | RBWH |
| Gynaecological | KEYNOTE A18 | A randomised, Phase 3, double-blind study of chemoradiotherapy with or without pembrolizumab for the treatment of high-risk, locally advanced cervical cancer. | RBWH |
| Gynaecological | ICON 9 | An international phase III randomised study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy | RBWH |
| Head and Neck | JNJ Saliva Study | Developing an Oral Rinse Method to Detect Human Papillomarvirus | RBWH |
| Head and Neck | SPIT | A simple saliva test to diagnose head and neck cancer at an early stage - head and neck cancer detection is a spitting distance away | RBWH |
| Head and Neck | P2191 | Development of an Adoptive T Cell Therapy for HPV-Associated Malignancies | RBWH |
| Head and Neck | C-POST | Phase III trial of postoperative radiotherapy with or without REGN2810 in high risk cutaneous squamous cell carcinoma of the head and neck (cSCCHN) | RBWH |
| Head and Neck | KEYNOTE 689 | A Phase 3, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination with Standard of Care as Adjuvant Therapy for Stage 3-IVB Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC) | RBWH |
| Head and Neck | CXCR4 | A Pilot Study of CXCR4 PET for nodal staging of resectable mucosal head and neck Squamous cell carcinoma (HNSCC), including correlation with histopathology immunohistochemistry, saliva and Circulating Tumour Cells | RBWH |
| Hodgkin Lymphoma | PLIMATH | A multi-centre Phase II study to determine the response kinetics, safety and efficacy of pembrolizumab as frontline treatment of patients with Hodgkin Lymphoma considered unsuitable for ABVD | RBWH |
| Lower GI | LYNK-003 | A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with 5-FU in Participants with Unresectable orMetastatic Colorectal Cancer who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003) | RBWH |
| Lower GI | CHALLENGE | A phase III study of the impact of a physical activity program on disease-free survival in patients with high risk stage II or stage III colon cancer: a randomised controlled trial | RBWH |
| Lower GI | ASCOLT | ASCOLT: Aspirin for Dukes C and high risk Dukes B colorectal cancers - an international, multi-centre, double blind, randomised placebo controlled phase III trial. | RBWH |
| Lower GI | RBWH & TPCH Database | The RBWH and TPCH metastatic Colorectal Cancer database: a prospective observational cohort study examining clinical and molecular biomarkers | RBWH |
| Lower GI | TRACC | TRACC (Biogrid): Study of Clinical Outcomes and Analysis of Bevacizumab use in Metastatic Colorectal Cancer | RBWH |
| Lower GI | MONARCC | A randomised phase II study of Panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer. | TPCH |
| Lower GI | DYNAMIC III (ctDNA-08) | Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Stage III Colon Cancer: A Multicentre Phase II/III Randomised Controlled Study | RBWH |
| Lower GI | MONARCC | A randomised phase II study of Panitumumab monotherapy and panitumumab plus 5 fluorouracil as first line therapy for RAS and BRAF wild type metastatic colorectal cancer. | RBWH |
| Lung | POPCORN | Pharmacodynamics of Pre-Operative PD1 CheckpOint Blockade and Receptor Activator of NF-κB Ligand (RANKL) Inhibition in Non-Small Cell Lung Cancer (NSCLC) – a phase 1B/2 trial | RBWH |
| Lung | KEYNOTE 867 | A Phase 3, Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Participants With Medically Inoperable Stages I or IIA Non Small Cell Lung Cancer (NSCLC) | RBWH |
| Metastatic NSCLC | LEAP007 | A Phase 3, randomized, double-blind trial of pembrolizumab (MK-3475) with or without lenvatinib (E7080/MK-7902) in participants with treatment-naïve, metastatic non-small cell lung cancer (NSCLC) whose tumors have a tumor proportion score (TPS) greater than or equal to 1% | TPCH |
| Metastatic NSCLC | LEAP006 | A Phase 3 Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab with or without Lenvatinib in Participants with NSCLC | TPCH |
| Metastatic NSCLC | LOXO-RET-18037 | A Multi-Center Expanded Access Program (EAP) for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors with Rearranged During Transfection (RET) Activation (LIBRETTO-201) | TPCH |
| Multiple Solid Tumours | Keynote 158 (BASKET) | A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects with Select Biomarker Positive Advanced Solid Tumors | RBWH |
| Multiple Solid Tumours | LEAP-005 | A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumours | RBWH |
| Myeloma | MRDR | Myeloma and Related Diseases Registry | RBWH |
| NETs | NET Sanguis | The potential role of circulating DNA in the management of neuroendocrine tumours. | RBWH |
| NSCLC | BFAST | A Phase II/III Multicenter study evaluating the efficacy and safety of multiple targeted therapies as treatments for patients with advanced or metastatic non-small cell lung cancer (NSCLC) harboring actionable somatic mutations detected in blood (B-Fast: Blood-first assay screening trial) | TPCH |
| Other | INFOCUS | Peripheral Neuropathy in Chemotherapy-treated Patients: Predictors, Assessment strategies and Functional Outcomes. INFOCUS Study | RBWH |
| Pancreas | FOLFIRINOX | Prospective evaluation of FOLFIRINOX for metastatic of locally advanced Pancreatic Cancer | RBWH |
| Pancreas | PURPLE | Pancreatic cancer: Understanding Routine Practice and Lifting End results (PURPLE) Registry. A Prospective Pancreatic Cancer clinical registry. | RBWH |
| Phase I / Brain | KB004 | A phase I safety and bioimaging trial of KB004 in patients with glioblastoma | RBWH |
| Phase I / Solid Tumours | Corvus CPI-444-001 | A Phase 1/1b, open-Label, multicentre, repeat-dose, dose-selection study of CPI-444 as single agent and in combination with Atezolizumab in patients with selected incurable cancers | RBWH |
| Phase I / Solid Tumours | Corvus CPI-006-001 | Phase 1/1b Multicenter Study to Evaluate the Humanized Anti-CD 73 Ab, CPI-006 as a Single Agent, in Combination With CPI-444 and in Combination with an Anti-PD(L)1 Antibody in Adult Subjects With Advanced Cancers | RBWH |
| Phase I / Solid Tumours | R3767-ONC-1613 | A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (Anti-LAG-3 mAb) Administered Alone or in Combination With REGN2810 (Anti-PD-1 mAb) in Patients With Advanced Malignancies | RBWH |
| Prostate | SPLIT-COURSE | A single arm, prospective Phase II study of Split-Course Pelvic Radiotherapy for Locally Progressive, Castrate Resistant Prostate Cancer | RBWH |
| Prostate | DASL-HICAP | A randomized phase 3 trial of adding darolutamide to radiation and androgen deprivation therapy in high risk, clinically localized prostate cancer - DASL-HiCaP: Darolutamide Augments Standard Therapy for Localized High-Risk Cancer of the Prostate | RBWH |
| Rectal | SPAR | A randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer | RBWH |
| Skin | CA209-7CK | A prospective, observational study in patients receiving adjuvant nivolumab therapy for resected melanoma in Australia | RBWH |
| Skin | CA209-76K | A Phase 3, Randomized, Double-Blind Study of Adjuvant Immunotherapy with Nivolumab versus Placebo after Complete Resection of Stage IIB/C Melanoma. | RBWH |
| Skin | CRIO | Chemoradiation for unresectable Skin Tumour with Immunotherapy | RBWH |
| Skin | R2810-ONC-1901 | A Phase II Study of Neoadjuvant Cemiplimab for Stage II-IV (M0) Cutaneous Squamous Cell Carcinoma (CSCC). | RBWH |
| Skin | R2810-ONC-1540 | A Phase 2 study of REGN2810, a fully human monoclonal anitbody to programmed death – 1 (PD1), in patients with advanced cutaneous squamous cell carcinoma | RBWH |
| Skin | STOP-GAP (ME-13) | A randomised phase III study of duration of Anti-PD-1 therapy in metastatic melanoma | RBWH |
| Skin | GoTHAM | A Merkel Cell Carcinoma (MCC) study testing the immunotherapy drug Avelumab in combination with either radionuclide therapy or external beam radiotherapy. | RBWH |
| Skin | CHARLI | A Phase Ib/II Trial of Ipilimumab-Nivolumab-Denosumab and Nivolumab-Denosumab in Patients with Unresectable Stage III and IV Melanoma. | RBWH |
| Thyroid | XL184-311 | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy | RBWH |
| Transplant | ALLG BM12 CAST |
Study of using Cyclophosphamide After Sibling-donor allogeneic stem-cell Transplantation (CAST) in patients with acute leukaemia and myelodysplasia: a randomised study comparing cyclosporin and methotrexate to cyclosporin and post-transplantation cyclophosphamide for graft-versus-host disease prophylaxis
|
RBWH |
| Transplant | Takeda GRAPHITE | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vedolizumab in the Prophylaxis of Intestinal Acute Graft-Versus-Host Disease in Subjects Undergoing Allogeneic Hematopoietic Stem Cell Transplantation | RBWH |
| Upper GI | INTEGRATE II | INTEGRATE II trial, a Phase III study of regorafenib in refractory advanced oesophago-gastric cancer (AOGC). | RBWH |
| Upper GI | ACTICCA-1 | Adjuvant Chemotherapy With Gemcitabine and Cisplatin Compared to Observation After Curative Intent Resection of Cholangiocarcinoma and Muscle Invasive Gall Bladder Carcinoma (ACTICCA-1 Trial) | RBWH |
| Upper GI | Dynamic Pancreas | Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Early Stage Pancreatic Cancer: A Multicentre Randomised Study | RBWH |
| Upper GI | EMERALD-1 | A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Transarterial Chemoembolization (TACE) in Combination with either Durvalumab Monotherapy or Durvalumab plus Bevacizumab Therapy in Patients with Locoregional Hepatocellular Carcinoma | RBWH |